Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy for localized head and neck squamous cell cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Anticancer Drugs. 2017 Apr;28(4):362-368. doi: 10.1097/CAD.0000000000000480. Anticancer Drugs. 2017. PMID: 28134662 Review.
Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Anticancer Drugs. 2017 Apr;28(4):357-361. doi: 10.1097/CAD.0000000000000473. Anticancer Drugs. 2017. PMID: 28166090 Review.
Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
Karabajakian A, Bouaoud J, Michon L, Kamal M, Crozes C, Zrounba P, Auclair-Perossier J, Gadot N, Attignon V, Le Tourneau C, Benzerdjeb N, Fayette J, Saintigny P. Karabajakian A, et al. Oral Oncol. 2021 Aug;119:105368. doi: 10.1016/j.oraloncology.2021.105368. Epub 2021 Jun 7. Oral Oncol. 2021. PMID: 34111704 Free article.
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C. Saâda-Bouzid E, et al. Among authors: karabajakian a. Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178. Ann Oncol. 2017. PMID: 28419181 Free article.
Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule.
Pêtre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J. Pêtre A, et al. Among authors: karabajakian a. Oncotarget. 2018 Apr 24;9(31):22038-22046. doi: 10.18632/oncotarget.25157. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774120 Free PMC article.
L’immunothérapie dans les cancers ORL.
Reverdy T, Gau M, Karabajakian A, Neidhardt EM, Fayette J. Reverdy T, et al. Among authors: karabajakian a. Bull Cancer. 2018 Dec;105 Suppl 1:S35-S42. doi: 10.1016/S0007-4551(18)30388-6. Bull Cancer. 2018. PMID: 30595197 Review. French.
19 results